Diagnosis and management of hyponatremia in acute illness

Current Opinion in Critical Care

Volumn 14, Issue 6, 2008, Pages 627-634

  Schrier, Robert W ^a,b   Bansal, Shweta ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Aquaretics; Hyponatremia; Hypoosmolality; Vasopressin

Indexed keywords

AMILORIDE PLUS HYDROCHLOROTHIAZIDE; ANTIDEPRESSANT AGENT; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; CHLORPROPAMIDE; CLOFIBRATE; CONIVAPTAN; CYCLOPHOSPHAMIDE; DEMECLOCYCLINE; LIXIVAPTAN; MORPHINE; MOZAVAPTAN; NEUROLEPTIC AGENT; NICOTINE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; SATAVAPTAN; SODIUM CHLORIDE; TOLBUTAMIDE; TOLVAPTAN; UREA; VASOPRESSIN; VINCRISTINE;

ARTERIAL PRESSURE; CLINICAL TRIAL; CRITICALLY ILL PATIENT; DISEASE CLASSIFICATION; EXERCISE; EXTRACELLULAR SPACE; FLUID INTAKE; HEART FAILURE; HEART OUTPUT; HUMAN; HYPONATREMIA; INAPPROPRIATE VASOPRESSIN SECRETION; REVIEW;

ACUTE DISEASE; HUMANS; HYPONATREMIA; OSMOLAR CONCENTRATION; OSMOTIC PRESSURE; RECEPTORS, VASOPRESSIN; VASOCONSTRICTOR AGENTS; VASOPRESSINS; WATER-ELECTROLYTE BALANCE; WATER-ELECTROLYTE IMBALANCE;

EID: 57149083284     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/MCC.0b013e32830e45e3     Document Type: Review

References (46)

1. DeVita MV, Gardenawartz MH, Konecky A, Zabetakis PM. Incidence and etiology of hyponatremia in an intensive care unit. Clin Nephrol 1990; 34:163-166.
2. Anderson RJ, Chung HM, Kluge R, Schrier RW. Hyponatremia: a prospective analysis of its epidemiology and the pathogenetic role of vasopressin. Ann Intern Med 1985; 102:164-168.
3. Upadhyay A, Jaber BL, Madias NE. Incidence and prevalence of hyponatremia. Am J Med 2006; 119 (7 Suppl 1):S30-S35.
4. Hoorn EJ, Lindemans J, Zietse R. Development of severe hyponatraemia in hospitalized patients: treatment-related risk factors and inadequate management. Nephrol Dial Transplant 2006; 21:70-76.
5. Schrier RW, Berl T, Anderson RJ. Osmotic and nonosmotic control of vasopressin release. Am J Physiol 1979; 236:F321-F332.
6. Robertson GL. Regulation of arginine vasopressin in the syndrome of in-appropriate antidiuresis. Am J Med 2006; 119 (7 Suppl 1):S36-S42.
7. Schrier RW. Decreased effective blood volume in edematous disorders: what does this mean? J Am Soc Nephrol 2007; 18:2028-2031.
8. Schrier RW. Body fluid volume regulation in health and disease: a unifying hypothesis. Ann Intern Med 1990; 113:155-159.
9. Miller TR, Anderson RJ, Linas SL, et al. Urinary diagnostic indices in acute renal failure: a prospective study. Ann Intern Med 1978; 89:47-50.
10. Schrier RW. Body water homeostasis: clinical disorders of urinary dilution and concentration. J Am Soc Nephrol 2006; 17:1820-1832.
11. Oren RM. Hyponatremia in congestive heart failure. Am J Cardiol 2005; 95 (9A):2B-7B.
12. Lee DS, Austin PC, Rouleau JL, et al. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA 2003; 290:2581-2587.
13. Chen MC, Chang HW, Cheng Cl, et al. Risk stratification of in-hospital mortality in patients hospitalized for chronic congestive heart failure secondary to nonischemic cardiomyopathy. Cardiology 2003; 100:136-142.
14. Biggins SW, Rodriguez HJ, Bacchetti P, et al. Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology 2005; 41:32-39.
15. Wu CC, Yeung LK, Tsai WS, et al. Incidence and factors predictive of acute renal failure in patients with advanced liver cirrhosis. Clin Nephrol 2006; 65:28-33.
16. Schrier RW. Water and sodium retention in edematous disorders: role of vasopressin and aldosterone. Am J Med 2006; 119 (7 Suppl 1):S47-S53.
17. Verbalis JG, Goldsmith SR, Greenberg A, et al. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med 2007; 120 (11 Suppl 1):S1-S21. Updated comprehensive review of guidelines of hyponatremia treatment.
18. Arieff AI, Llach F, Massry SG. Neurological manifestations and morbidity of hyponatremia: correlation with brain water and electrolytes. Medicine (Baltimore) 1976; 55:121-129.
19. Verbalis JG. AVP receptor antagonists as aquaretics: review and assessment of clinical data. Cleve Clin J Med 2006; 73 (Suppl 3):S24-S33.
20. Schrier RW. The sea within us: disorders of body water homeostasis. Curr Opin Investig Drugs 2007; 8:304-311.
21. Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. J Am Coll Cardiol 2005; 46:1785-1791.
22. Thibonnier M, Conarty DM, Preston JA, et al. Molecular pharmacology of human vasopressin receptors. Adv Exp Med Biol 1998; 449:251-276.
23. Greenberg A, Verbalis JG. Vasopressin receptor antagonists. Kidney Int 2008; 69:2124-2130.
24. Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006; 355:2099-2112.
25. Ayus JC, Arieff AI. Chronic hyponatremic encephalopathy in postmenopausal women: association of therapies with morbidity and mortality. JAMA 1999; 281:2299-2304.
26. Verbalis JG. Disorders of body water homeostasis. Best Pract Res Clin Endocrinol Metab 2003; 17:471-503.
27. Gross P, Reimann D, Henschkowski J, Damian M. Treatment of severe hyponatremia: conventional and novel aspects. J Am Soc Nephrol 2001; 12 (Suppl 17):S10-S14.
28. Sterns RH, Cappuccio JD, Silver SM, Cohen EP. Neurologic sequelae after treatment of severe hyponatremia: a multicenter perspective. J Am Soc Nephrol 1994; 4:1522-1530.
29. Karp BI, Laureno R. Pontine and extrapontine myelinolysis: a neurologic disorder following rapid correction of hyponatremia. Medicine (Baltimore) 1993; 72:359-373.
30. Ellison DH, Berl T. Clinical practice. The syndrome of inappropriate antidiuresis. N Engl J Med 2007; 356:2064-2072. An excellent review on the management of SIADH.
31. Adrogue HJ, Madias NE. Hyponatremia. N Engl J Med 2000; 342:1581-1589.
32. Mohmand HK, Issa D, Ahmad Z, et al. Hypertonic saline for hyponatremia: risk of inadvertent overcorrection. Clin J Am Soc Nephrol 2007; 2:1110-1117. Retrospective review to assess the accuracy of Adrogue-Madias formula and the pattern of hypertonic saline use and the impact of recent guidelines to correct hyponatremia on the outcome and safety.
33. Liamis G, Kalogirou M, Saugos V, Elisaf M. Therapeutic approach in patients with dysnatraemias. Nephrol Dial Transplant 2006; 21:1564-1569.
34. Barsoum NR, Levine BS. Current proscriptions for the correction of hyponatraemia and hypernatraemia: are they too simple? Nephrol Dial Transplant 2002; 17:1176-1180.
35. Cherrill DA, Stote RM, Birge JR, Singer I. Demeclocycline treatment in the syndrome of inappropriate antidiuretic hormone secretion. Ann Intern Med 1975; 83:654-656.
36. Dousa TP, Wilson DM. Effects of demethylchlortetracycline on cellular action of antidiuretic hormone in vitro. Kidney Int 1974; 5:279-284.
37. Miller PD, Linas SL, Schrier RW. Plasma demeclocycline levels and nephrotoxicity. Correlation in hyponatremic cirrhotic patients. JAMA 1980; 243:2513-2515.
38. Zegers de Beyl D, Naeije R, de Troyer A. Demeclocycline treatment of water retention in congestive heart failure. BMJ 1978; 1:760.
39. Decaux G, Mols P, Cauchi P, Delwiche F. Use of urea for treatment of water retention in hyponatraemic cirrhosis with ascites resistant to diuretics. BMJ (Clin Res Ed) 1985; 290:1782-1783.
40. Forrest JN Jr, Cox M, Hong C, et al. Superiority of demeclocycline over lithium in the treatment of chronic syndrome of inappropriate secretion of antidiuretic hormone. N Engl J Med 1978; 298:173-177.
41. Sonnenblick M, Friedlander Y, Rosin AJ. Diuretic-induced severe hyponatremia. Review and analysis of 129 reported patients. Chest 1993; 103:601-606.
42. Schwartz WB, Bennett W, Curelop S, Bartter FC. A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone. Am J Med 1957; 23:529-542.
43. Sterns RH, Silver SM. Cerebral salt wasting versus SIADH: what difference? J Am Soc Nephrol 2008; 19:194-196. A clinical commentary discussing whether there is any difference between cereral salt wasting and SIADH and whether the difference is important.
44. Almond CS, Shin AY, Fortescue EB, et al. Hyponatremia among runners in the Boston Marathon. N Engl J Med 2005; 352:1550-1556.
45. Noakes T. Fluid replacement during marathon running. Clin J Sport Med 2003; 13:309-318.
46. Hew-Butler T, Almond C, Ayus JC, et al. Consensus statement of the 1st International Exercise-Associated Hyponatremia Consensus Development Conference, Cape Town, South Africa 2005. Clin J Sport Med 2005; 15:208-213.